3 hours HC Wainwright Reiterates Buy Rating for Jasper Therapeutics (NASDAQ:JSPR)MarketBeat
HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday.
XHC Wainwright reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday.
X